vs
安朗杰（ALLE）与莫德纳（MRNA）财务数据对比。点击上方公司名可切换其他公司
安朗杰的季度营收约是莫德纳的1.0倍（$1.0B vs $1.0B），安朗杰净利率更高（13.4% vs -19.7%，领先33.0%），安朗杰同比增速更快（9.7% vs -45.4%），过去两年安朗杰的营收复合增速更高（3.5% vs -45.0%）
安朗杰是全球知名的安防产品及解决方案供应商，面向全球生产销售机械与电子类安防产品，包括闭门器、出入口控制设备、锁具、电子门禁系统、考勤与人员效能管理系统、门体系统及相关配件，服务商业、公共机构、住宅等多领域终端用户
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
ALLE vs MRNA — 直观对比
营收规模更大
ALLE
是对方的1.0倍
$1.0B
营收增速更快
ALLE
高出55.2%
-45.4%
净利率更高
ALLE
高出33.0%
-19.7%
两年增速更快
ALLE
近两年复合增速
-45.0%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.0B |
| 净利润 | $138.1M | $-200.0M |
| 毛利率 | 44.0% | 79.6% |
| 营业利润率 | 18.9% | -25.6% |
| 净利率 | 13.4% | -19.7% |
| 营收同比 | 9.7% | -45.4% |
| 净利润同比 | -6.8% | -1638.5% |
| 每股收益（稀释后） | — | $-0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALLEMRNA
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $941.9M | — | ||
| Q4 24 | $945.6M | $966.0M | ||
| Q3 24 | $967.1M | $1.9B | ||
| Q2 24 | $965.6M | — |
净利润ALLEMRNA
| Q1 26 | $138.1M | — | ||
| Q4 25 | $147.5M | — | ||
| Q3 25 | $188.4M | $-200.0M | ||
| Q2 25 | $159.7M | — | ||
| Q1 25 | $148.2M | — | ||
| Q4 24 | $144.1M | $-1.1B | ||
| Q3 24 | $174.2M | $13.0M | ||
| Q2 24 | $155.4M | — |
毛利率ALLEMRNA
| Q1 26 | 44.0% | — | ||
| Q4 25 | 44.5% | — | ||
| Q3 25 | 45.8% | 79.6% | ||
| Q2 25 | 45.6% | — | ||
| Q1 25 | 44.9% | — | ||
| Q4 24 | 44.1% | 23.5% | ||
| Q3 24 | 44.7% | 72.4% | ||
| Q2 24 | 44.4% | — |
营业利润率ALLEMRNA
| Q1 26 | 18.9% | — | ||
| Q4 25 | 20.3% | — | ||
| Q3 25 | 21.8% | -25.6% | ||
| Q2 25 | 21.5% | — | ||
| Q1 25 | 20.9% | — | ||
| Q4 24 | 19.5% | -129.0% | ||
| Q3 24 | 22.2% | -3.8% | ||
| Q2 24 | 21.6% | — |
净利率ALLEMRNA
| Q1 26 | 13.4% | — | ||
| Q4 25 | 14.3% | — | ||
| Q3 25 | 17.6% | -19.7% | ||
| Q2 25 | 15.6% | — | ||
| Q1 25 | 15.7% | — | ||
| Q4 24 | 15.2% | -115.9% | ||
| Q3 24 | 18.0% | 0.7% | ||
| Q2 24 | 16.1% | — |
每股收益（稀释后）ALLEMRNA
| Q1 26 | — | — | ||
| Q4 25 | $1.70 | — | ||
| Q3 25 | $2.18 | $-0.51 | ||
| Q2 25 | $1.85 | — | ||
| Q1 25 | $1.71 | — | ||
| Q4 24 | $1.65 | $-2.91 | ||
| Q3 24 | $1.99 | $0.03 | ||
| Q2 24 | $1.77 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $308.9M | $1.1B |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $2.1B | $9.3B |
| 总资产 | $5.3B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.97× | — |
8季度趋势，按日历期对齐
现金及短期投资ALLEMRNA
| Q1 26 | $308.9M | — | ||
| Q4 25 | $356.2M | — | ||
| Q3 25 | $302.7M | $1.1B | ||
| Q2 25 | $656.8M | — | ||
| Q1 25 | $494.5M | — | ||
| Q4 24 | $503.8M | $1.9B | ||
| Q3 24 | $878.9M | $1.6B | ||
| Q2 24 | $747.5M | — |
总债务ALLEMRNA
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益ALLEMRNA
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.9B | $9.3B | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.5B | $10.9B | ||
| Q3 24 | $1.6B | $11.9B | ||
| Q2 24 | $1.4B | — |
总资产ALLEMRNA
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.2B | $12.1B | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $4.6B | — | ||
| Q4 24 | $4.5B | $14.1B | ||
| Q3 24 | $5.0B | $15.8B | ||
| Q2 24 | $4.8B | — |
负债/权益比ALLEMRNA
| Q1 26 | 0.97× | — | ||
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 1.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $101.3M | $-847.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-880.0M |
| 自由现金流率自由现金流/营收 | — | -86.6% |
| 资本支出强度资本支出/营收 | 2.0% | 3.2% |
| 现金转化率经营现金流/净利润 | 0.73× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.9B |
8季度趋势，按日历期对齐
经营现金流ALLEMRNA
| Q1 26 | $101.3M | — | ||
| Q4 25 | $240.1M | — | ||
| Q3 25 | $229.5M | $-847.0M | ||
| Q2 25 | $209.7M | — | ||
| Q1 25 | $104.5M | — | ||
| Q4 24 | $219.0M | $825.0M | ||
| Q3 24 | $231.9M | $-1.6B | ||
| Q2 24 | $173.0M | — |
自由现金流ALLEMRNA
| Q1 26 | — | — | ||
| Q4 25 | $200.5M | — | ||
| Q3 25 | $209.8M | $-880.0M | ||
| Q2 25 | $192.0M | — | ||
| Q1 25 | $83.4M | — | ||
| Q4 24 | $194.9M | $303.0M | ||
| Q3 24 | $212.0M | $-1.7B | ||
| Q2 24 | $152.1M | — |
自由现金流率ALLEMRNA
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | — | ||
| Q3 25 | 19.6% | -86.6% | ||
| Q2 25 | 18.8% | — | ||
| Q1 25 | 8.9% | — | ||
| Q4 24 | 20.6% | 31.4% | ||
| Q3 24 | 21.9% | -92.2% | ||
| Q2 24 | 15.8% | — |
资本支出强度ALLEMRNA
| Q1 26 | 2.0% | — | ||
| Q4 25 | 3.8% | — | ||
| Q3 25 | 1.8% | 3.2% | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.5% | 54.0% | ||
| Q3 24 | 2.1% | 8.1% | ||
| Q2 24 | 2.2% | — |
现金转化率ALLEMRNA
| Q1 26 | 0.73× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 1.52× | — | ||
| Q3 24 | 1.33× | -120.46× | ||
| Q2 24 | 1.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALLE
| Allegion Americas | $809.9M | 78% |
| Allegion International | $223.7M | 22% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
